1-855-378-42281-855-378-4228
One of the out-patient treatment options for people in Glenwood who are battling with opioid abuse and addiction is opioid maintenance therapy. Some centers and doctors are certified to administer specific medications to opioid addicted people, many of which are opioids themselves and are addictive. With low doses however, the client doesn't experience high feelings and also doesn't have intense cravings and is not in opioid withdrawal. Methadone is the first med administered for this sole purpose, but there are a few more choices to choose from.
Methadone is an opiate and is meant to be taken at an out-patient medical center certified to administer the drug, which is taken on a daily basis in liquid or pill form. The cost of the med is about one hundred and fifty dolloars a month. Buprenorphine is also an opiate based med, and is a pill often taken every other day. But different from Methadone that is only be dispensed in highly structured medical centers, Buprenorphine can be prescribed and dispensed in doctor's offices. The monthly cost of buprenorphine is approximately three hundred dollars monthly for the generic version of the medication. There is also a version of buprenorphine that contains naloxone, which is a drug that blocks the effects of opioids. A person consuming this formulation, also known as Suboxone, would find it more difficult to get high from opioids if they relapsed while taking the drug. It is also taken every day, and is priced around $450 per month. Naltrexone is an additional drug used in opioid maintenance therapy, but unlike the other drugs aforementioned it's an opioid blocker and isn't an opioid. A person has the choice to take this medication as a monthly shot, and that is called Vivitrol. As an opioid blocker, the drug prevents an individual from feeling high from opioids, and in turn lowers the risk associated with relapse. This daily shot costs in the range of $1000 to $1200 per month.
For All Alcohol and Drug Rehab Facilities In Glenwood, Click Here.
